Updates on lung cancer from WCLC and ESMO 2023

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer

Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer

ESMO 2023: Highlights and analysis

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Where do we stand with mCRPC?

PARPi combinations to treat patients with mCRPC

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer 

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+ HER2− breast cancer

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer

Belzutifan improves PFS, ORR in clear cell renal cell carcinoma

Effects of short-term fasting on quality of life as an add-on option during chemotherapy

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC

Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC

Genomic testing: Awareness and effective communication between healthcare professionals and patients

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Durvalumab addition to chemo shows endometrial cancer benefit

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer

CheckMate-77T: Perioperative nivolumab benefit for NSCLC